These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 21826093)

  • 21. Advances in targeted therapies XII. Preface.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1. PubMed ID: 21339210
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
    Tarnowski M; Paradowska-Gorycka A; Dąbrowska-Zamojcin E; Czerewaty M; Słuczanowska-Głąbowska S; Pawlik A
    Expert Opin Drug Metab Toxicol; 2016; 12(1):41-55. PubMed ID: 26609565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010.
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1-122. PubMed ID: 21438187
    [No Abstract]   [Full Text] [Related]  

  • 24. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.
    Díaz-Borjón A
    Drugs Aging; 2009; 26(4):273-93. PubMed ID: 19476397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine.
    Seidman EG; Furst DE
    J Rheumatol; 2002 Dec; 29(12):2484-7. PubMed ID: 12465139
    [No Abstract]   [Full Text] [Related]  

  • 26. [Personalized medicine in rheumatology].
    Szekanecz Z
    Orv Hetil; 2013 Mar; 154(13):483-96. PubMed ID: 23524232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A; Urano W; Tanaka E; Akama H; Yamanaka H; Kamatani N
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.
    Polk BI; Becker ML
    Discov Med; 2013 Dec; 16(90):267-75. PubMed ID: 24333406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture.
    Cronstein BN
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):2-3. PubMed ID: 16932642
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenetics in the rheumatic diseases.
    Cronstein BN
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii25-ii27. PubMed ID: 15479867
    [No Abstract]   [Full Text] [Related]  

  • 31. An update on methotrexate.
    Braun J; Rau R
    Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing incidence of orthopedic surgery in rheumatic disease: contributing factors.
    Bernstein EJ; Mandl LA
    Curr Rheumatol Rep; 2013 Oct; 15(10):365. PubMed ID: 23955065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proposal for a new nomenclature of disease-modifying antirheumatic drugs.
    Smolen JS; van der Heijde D; Machold KP; Aletaha D; Landewé R
    Ann Rheum Dis; 2014 Jan; 73(1):3-5. PubMed ID: 24072562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?
    Sutcliffe M; Radley G; Barton A
    Expert Rev Clin Immunol; 2020 Apr; 16(4):389-396. PubMed ID: 32176556
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology.
    Mok CC; Tam LS; Chan TH; Lee GK; Li EK;
    Clin Rheumatol; 2011 Mar; 30(3):303-12. PubMed ID: 21046421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic treatments for systemic rheumatic diseases.
    Shirota Y; Illei GG; Nikolov NP
    Oral Dis; 2008 Apr; 14(3):206-16. PubMed ID: 18282173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.